Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.
Hiroaki IwamotoKouji IzumiRyunosuke NakagawaRen ToriumiShuhei AoyamaTakafumi ShimadaHiroshi KanoTomoyuki MakinoSuguru KadomotoHiroshi YaegashiShohei KawaguchiTakahiro NoharaKazuyoshi ShigeharaYoshifumi KadonoAtsushi MizokamiPublished in: Japanese journal of clinical oncology (2022)
This study demonstrated the utility of serum chemokine (CC motif) ligand 2 level as a predictive biomarker of long-term overall survival in prostate cancer. A novel risk classification system that predicts long-term overall survival based on the combined indications of chemokine (CC motif) ligand 2 level, prostate-specific antigen level and Gleason score may be a useful prognostic tool for prostate cancer.